ROCHELLE PARK, N.J.--(BUSINESS WIRE)--Reflecting continued growth and stature in the industry, TKL Research, a full-service clinical research organization (CRO), will unveil a larger island exhibit at the American Academy of Dermatology (AAD) Annual Meeting, March 20-24 at the Moscone Center in San Francisco.
“TKL has grown substantially, both with our proprietary research clinics as well as in clinical trial management services for all phases of drug development,” said Dr. Jon Anderson, TKL Research president and CEO. “For AAD, we designed an environment with our new booth space to elicit interest from attendees who know us as well as those who have not heard of us.”
TKL Research is an international CRO serving the pharmaceutical, biotech, generic drug, medical device, OTC, and consumer health care industries. The leader in dermatological research, TKL has performed over 200 dermatological clinical trials, and is unrivaled in the number of dermatological safety studies. TKL also has significant experience in Phase 1 to 4 multinational clinical trials, and differentiates itself from the competition with a strong Phase 1 safety capability and full service CRO combined into one cohesive organization.
“We give clients a competitive edge by accelerating trials through our innovations and excellence in recruitment expertise,” Anderson said. “Our clients have rewarded us with an increasing stream of research studies worldwide.”
Of particular interest to attendees of AAD, TKL will feature our new state-of-the-art phase 1 facility as well as case histories involving recent research in Actinic Keratosis. TKL will also discuss current and upcoming educational offerings, including a webinar in April discussing risk-based monitoring to improve clinical data quality.
For more information, visit TKL Research at booth 412 at the AAD Annual Meeting or online at tklresearch.com.
About TKL Research, Inc.
TKL Research is a full-service, international CRO offering deep expertise in a full spectrum of dermatological indications as well as a complete range of clinical trial management services from Phase 1 to multicenter international studies. TKL’s emphasis on recruitment and site selection enables studies to be filled and initiated sooner, shortening timelines and reducing costs for a wide range of studies in dermatology and other therapeutic areas.